Miladys Limonta‐Fernández

Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)

Francisco Hernández‐Bernal, Maria C. Ricardo-Cobas, Yenima Martín‐Bauta et al. · EClinicalMedicine · 2022 · 69 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen

Miladys Limonta‐Fernández, Glay Chinea-Santiago, Alejandro Miguel Martín-Dunn et al. · New Biotechnology · 2022 · 57 citations · Full text

Life Sciences, Biotechnology, Immunology +17

Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study

Pedro I. Más-Bermejo, Félix O. Dickinson-Meneses, Kenia Almenares-Rodríguez et al. · The Lancet Regional Health - Americas · 2022 · 35 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti‐hepatitis B vaccination

Marlén Castellanos, Zurina Cinza, Zaily Dorta Guridi et al. · The Journal of Gene Medicine · 2009 · 27 citations

Veterinary Medicine, Immunology, Infectious Diseases +17

Recombinant Human Epidermal Growth Factor/Quatsome Nanoconjugates: A Robust Topical Delivery System for Complex Wound Healing

Lidia Ferrer‐Tasies, Héctor Santana, Ingrid Cabrera‐Puig et al. · Advanced Therapeutics · 2021 · 24 citations · Full text

Pharmacy, Biotechnology, Pharmaceutics +17